- Home
- SUGP vs MIRA Comparison
SUGP vs MIRA Comparison
Compare SUGP & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- MIRA
- Stock Information
- Founded
- SUGP 1998
- MIRA 2020
- Country
- SUGP Hong Kong
- MIRA United States
- Employees
- SUGP N/A
- MIRA N/A
- Industry
- SUGP
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- MIRA Health Care
- Exchange
- SUGP NYSE
- MIRA Nasdaq
- Market Cap
- SUGP 20.3M
- MIRA 21.2M
- IPO Year
- SUGP 2024
- MIRA 2023
- Fundamental
- Price
- SUGP $0.98
- MIRA $1.09
- Analyst Decision
- SUGP
- MIRA Strong Buy
- Analyst Count
- SUGP 0
- MIRA 2
- Target Price
- SUGP N/A
- MIRA $14.00
- AVG Volume (30 Days)
- SUGP 67.1K
- MIRA 493.9K
- Earning Date
- SUGP 02-02-2025
- MIRA 11-12-2024
- Dividend Yield
- SUGP N/A
- MIRA N/A
- EPS Growth
- SUGP N/A
- MIRA N/A
- EPS
- SUGP 0.10
- MIRA N/A
- Revenue
- SUGP $20,252,232.00
- MIRA N/A
- Revenue This Year
- SUGP N/A
- MIRA N/A
- Revenue Next Year
- SUGP N/A
- MIRA N/A
- P/E Ratio
- SUGP $10.13
- MIRA N/A
- Revenue Growth
- SUGP N/A
- MIRA N/A
- 52 Week Low
- SUGP $0.76
- MIRA $0.51
- 52 Week High
- SUGP $5.86
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- SUGP 33.64
- MIRA 37.31
- Support Level
- SUGP $0.76
- MIRA $1.04
- Resistance Level
- SUGP $1.65
- MIRA $1.16
- Average True Range (ATR)
- SUGP 0.23
- MIRA 0.10
- MACD
- SUGP -0.09
- MIRA -0.02
- Stochastic Oscillator
- SUGP 19.82
- MIRA 24.29
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.